- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00669539
Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old (ATS13)
An Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old
Study Overview
Status
Conditions
Detailed Description
This study will evaluate the effectiveness of refractive correction alone for the treatment of previously untreated strabismic or combined-mechanism amblyopia in children 3 to <7 years old with visual acuity of 20/40 to 20/400.
A recently completed PEDIG study (ATS5) found that in 3 to < 7-year-old children with previously untreated anisometropic amblyopia, refractive correction alone improved visual acuity by 2 or more lines in 77% of the patients and amblyopia resolved in at least one third of the patients. These results supported previous observations from retrospective and pilot studies as well as Stewart et al's prospective report on 18 children with anisometropic amblyopia whose visual acuity improved after treatment with spectacle correction only.
Improvement in amblyopic eye visual acuity from treatment with optimum refractive correction in cases of anisometropic amblyopia is plausible because the refractive correction treats the underlying amblyogenic condition (i.e., uncorrected unequal refractive error) by providing retinal images of more similar clarity, size, and contrast. Elimination of the dissimilar retinal images, which may act as barriers to normal visual input, allows the amblyopic eye to receive appropriate visual stimulation. In contrast, visual acuity improvement with refractive correction alone in cases of amblyopia associated with strabismus is not expected to occur when the refractive correction does not completely eliminate the strabismus and restore fusion. In such cases, the underlying amblyogenic factor of a manifest ocular deviation remains; consequently, active cortical inhibition is presumably still present. Nonetheless, Stewart and colleagues recently reported finding gains in amblyopic eye visual acuity of children with strabismic and combined-mechanism amblyopia after a period of treatment with refractive correction alone. The PEDIG also observed this to occur in a subgroup of children with previously untreated strabismic and combined-mechanism amblyopia in a recent study. Amblyopic eye acuity improved by >= 2 lines from spectacle-corrected baseline acuity in 9 (75%; 95% CI = 43% - 95%) of the 12 patients with strabismic amblyopia and in 9 (69%, 95% CI = 39% - 91%) of the 13 patients with combined-mechanism amblyopia. Mean change from baseline to maximum improvement was 2.2 +- 1.8 and 2.6 +- 2.0 lines, respectively. These results are similar to those of Stewart and colleagues who reported visual acuity improvement averaging 3.0 lines in 16 children with strabismic amblyopia and 1.9 lines in 31 children with combined-mechanism amblyopia.
Although our results support the suggestion of Stewart et al. that strabismic amblyopia can improve with spectacle correction alone, they are not conclusive because both studies had small numbers of patients. Also, our classification of strabismus was based on alignment without refractive correction. Thus, a larger controlled study is needed to confirm or refute these findings in patients with strabismic and combined-mechanism amblyopia.
The ideal study design to answer the question of whether spectacles alone can significantly improve amblyopic eye visual acuity in strabismic children is a randomized trial with a control group who does not receive optical correction. However, most pediatric eye care providers would be reluctant to randomize esotropic children with hyperopic refractive error to a control group of no optical correction because of the likelihood of some children having accommodative esotropia, which would necessitate that hyperopic spectacles be prescribed. The number of esotropic amblyopes without an accommodative component is sufficiently few to make a randomized trial not feasible. Therefore, we have chosen to perform an observational study with a large number of children with pure strabismic and combined-mechanism amblyopia in order to evaluate the effect of refractive correction in this population of patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
Fullerton, California, United States, 92831-1699
- Southern California College of Optometry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 3 to <7 years old
- Able to perform visual acuity testing using the ATS single-surround HOTV protocol
Amblyopia associated with strabismus (comitant or incomitant) with or without anisometropia
*At least one of the following criteria must be met:
- Heterotropia at distance and/or near fixation on examination (without spectacles)
- History of strabismus surgery (or botulinum toxin extraocular muscle injection)
- Documented history of strabismus that is no longer present (and which in the judgment of the investigator is the cause of amblyopia)
Visual acuity measured in each eye according to the protocol procedures that meet the following criteria:
- Amblyopic eye 20/40 to 20/400 inclusive
- Sound eye >=20/40
- Inter-eye acuity difference >= 3 logMAR lines (i.e., amblyopic eye acuity at least 3 logMAR lines worse than sound eye acuity)
- No previous spectacle correction
- Refractive error meeting at least 1 of the following criteria: >= 1.00D of astigmatism in the amblyopic eye, >= 1.00D spherical equivalent anisometropia, or >= +2.00D spherical equivalent hyperopia in either eye.
- Investigator wishes to prescribe spectacles to correct refractive error
- Nystagmus per se does not exclude the patient if the above visual acuity criteria are met
- Ocular examination within 2 months prior to enrollment
- Cycloplegic refraction within 2 months prior to enrollment
- No myopia = -0.25D spherical equivalent)
- Parent understands protocol and is willing to accept treatment
- Parent has home phone (or access to phone) and is willing to be contacted by Jaeb Center staff
- Relocation outside of area of an active ATS site within next 6 months not anticipated
Exclusion Criteria:
- Prior amblyopia treatment
- Current vision therapy or orthoptics
- Ocular cause for reduced visual acuity
- Prior intraocular or refractive surgery
- Strabismus surgery planned in the 9 weeks following the Baseline Visit
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Combined-Mechanism Amblyopia
|
Strabismus-Only Amblyopia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Amblyopic Eye Visual Acuity Improvement With Spectacles
Time Frame: Enrollment to 18 Weeks
|
Acuity is measured in each eye using the Amblyopia Treatment Study (ATS) visual acuity testing protocol at baseline and at 18wks resulting in a Snellen acuity score that can range from 20/16 to 20/800.
The score is converted to logMAR (log of min angle of resolution) for statistical analysis, and a difference between the scores is calculated.
A positive difference indicates acuity was better at 18wks than at baseline; a negative difference indicates acuity was worse at 18wks than at baseline.
|
Enrollment to 18 Weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Susan A. Cotter, O.D., M.S., Southern California College of Optometry at Marshall B. Ketchum University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEI-139
- 2U10EY011751 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amblyopia
-
Universitat Politècnica de CatalunyaParc Sanitari Sant Joan de Déu; Hospital Mutua de TerrassaCompletedAmblyopia | Anisometropic Amblyopia | Strabismic Amblyopia | Amblyopia Occlusion | Unilateral AmblyopiaSpain
-
Vedea Healthware BVElisabeth-TweeSteden Ziekenhuis; Jeroen Bosch Ziekenhuis; Health Holland; Oogziekenhuis... and other collaboratorsRecruitingAmblyopia | Amblyopia, Anisometropic | Amblyopia StrabismicNetherlands
-
Universitat Politècnica de CatalunyaHospital Mutua de TerrassaCompletedAmblyopia | Anisometropic Amblyopia | Strabismic AmblyopiaSpain
-
Alaska Blind Child DiscoveryCompletedStrabismus | Strabismic Amblyopia | Refractive AmblyopiaUnited States
-
Baylor College of MedicineActive, not recruitingHyperopia | High Myopia | Anisometropia | Amblyopia Isometropic | Amblyopia Bilateral | High AstigmatismUnited States
-
Medical University of ViennaRecruitingAmblyopia ex Strabismus | Amblyopia ex AnisometropiaAustria
-
National Cheng-Kung University HospitalChang Gung Memorial HospitalCompletedAmblyopia | Amblyopia, Anisometropic
-
Shahid Beheshti University of Medical SciencesUnknownThe New Treatment in Amblyopia TherapyIran, Islamic Republic of
-
University of BaselUniversity Medical Center NijmegenWithdrawnStrabismic Amblyopia
-
Wenzhou Medical UniversityUnknown